Ascites, Cirrhosis
Conditions
Brief summary
Effects of long term albumin administration on the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.
Detailed description
Pharmacodynamic study of pathophysiological nature to assess the effects of prolonged administration of human albumin in the cardiocirculatory and renal function and hepatic hemodynamics in patients with advanced cirrhosis and ascites.
Interventions
DRUGAlbumin
The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
Sponsors
Hospital Clinic of Barcelona
Instituto Grifols, S.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age above 18 years and less than 80 years. * Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound. * Daily requirement of diuretics at least 200mg of spironolactone or 100mg of spironolactone and 40 mg of furosemide * Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl, blood urea nitrogen ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L.
Exclusion criteria
* Refractory Ascites (paracentesis requirements over 1 month. * Neoplastic disease including liver cancer if it exceeds the Milan criteria (one nodule\> 5 cm or three nodules\> 3 cm). * History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt * Gastrointestinal bleeding or bacterial infection documented in the past 15 days. * Heart failure or structural heart disease. * Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data nephropathy). * Moderate or severe lung chronic disease. * Transplant. * Infection with human immunodeficiency virus. * Active addiction to drugs. * Mental state that prevents the patient understand the nature, extent and consequences of the study, except for hepatic encephalopathy. * Pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To asses change from Baseline plasma renin concentration at Week 14 | 14 weeks | Plasma renin activity will be measured at Baseline and Week 14 |
| To asses change from Baseline plasma renin concentration at Week 20 | 20 weeks | Plasma renin activity will be measured at Baseline and Week 20 |
| To asses change from Baseline plasma concentration of noradrenaline at week 14 | 14 weeks | Plasma noradrenaline concentration will be measured at Baseline and Week 14 |
| To asses change from Baseline plasma concentration of noradrenaline at Week 20 | 20 weeks | Plasma noradrenaline concentration will be measured at Baseline and Week 20 |
| To assess change from Baseline glomerular filtration rate at Week 14 | 14 weeks | Glomerular filtration rate will be measured at Baseline and Week 14 |
| To assess change from Baseline glomerular filtration rate at Week 20 | 20 weeks | Glomerular filtration rate will be measured at Baseline and Week 20 |
| To assess change from Baseline cardiac output at Week 14 | 14 weeks | Cardiac output will be measured at Baseline and Week 14 |
| To assess change from Baseline cardiopulmonary pressures at Week 14 | 14 weeks | Cardiopulmonary pressures will be measured at Baseline and Week 14 |
| To assess change from Baseline free hepatic pressure at Week 14 | 14 weeks | Free hepatic pressure will be measured at Baseline and Week 14 |
| To assess change from Baseline wedged hepatic pressure at Week 14 | 14 weeks | Wedged hepatic pressure will be measured at Baseline and Week 14 |
| To assess change from Baseline echocardiography at Week 14 | 14 weeks | Echocardiography will be measured at Baseline and Week 14 |
Countries
Spain
Outcome results
None listed